Invion Limited
Research Invion Limited (7C8) on Bullrun: market cap EUR 2.29M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker7C8
- ExchangeF
- CountryAustralia
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 2.29M
- Financial periodFY2025
- Net income-AUD 8.81M
- Free cash flow-AUD 2.97M
Valuation Snapshot
latest market cap is EUR 2.29M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -AUD 8.81M | -AUD 2.97M | n/a | -0.12 | AUD 850.37K | n/a | AUD 8.25M |
| FY2024 | AUD 3.69M | -AUD 5.63M | -AUD 3.30M | 100.0% | -0.09 | AUD 783.53K | n/a | AUD 14.44M |
| FY2023 | AUD 4.10M | -AUD 1.61M | -AUD 4.39M | 100.0% | -0.03 | AUD 4.08M | n/a | AUD 18.40M |
| FY2022 | AUD 3.29M | -AUD 2.24M | -AUD 8.36M | 100.0% | -0.04 | AUD 8.47M | n/a | AUD 19.58M |
| FY2021 | AUD 2.33M | n/a | n/a | 100.0% | n/a | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 2.29M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Invion Limited
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme (GBM), lung, and ovarian cancers; and human papilloma virus.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Invion Limited's market cap?
Invion Limited's market capitalization is EUR 2.29M.
What does Invion Limited do?
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme (GBM), lung, and ovarian cancers; and human papilloma virus.